Matching articles for "vaccination"

Seasonal Trivalent Influenza Vaccine for 2010-2011

   
The Medical Letter on Drugs and Therapeutics • October 4, 2010;  (Issue 1348)
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of...
Annual vaccination against influenza A and B viruses is the most effective method of preventing influenza. An upcoming issue of The Medical Letter will review drugs for chemoprophylaxis and treatment of influenza.
Med Lett Drugs Ther. 2010 Oct 4;52(1348):77-9 | Show Full IntroductionHide Full Introduction

Pneumococcal Vaccination of Adults: Polysaccharide or Conjugate?

   
The Medical Letter on Drugs and Therapeutics • June 15, 2009;  (Issue 1314)
A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic...
A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic pneumonia), but not mortality, in immunocompetent older adults.2 PPSV23 has not been shown to reduce the risk of invasive pneumococcal disease (IPD) in immunocompromised patients.

Click here to view the free full article.
Med Lett Drugs Ther. 2009 Jun 15;51(1314):47-8 | Show Full IntroductionHide Full Introduction

Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults

   
The Medical Letter on Drugs and Therapeutics • January 16, 2006;  (Issue 1226)
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine tetanus-diphtheria (Td) boosters in adolescents 11-18 years old, and Adacel should replace Td boosters in adults 19-64 years old.
Med Lett Drugs Ther. 2006 Jan 16;48(1226):5-6 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Prophylaxis and Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • November 21, 2005;  (Issue 1222)
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in...
Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status.
Please see Update: Influenza Resistance to Amantadine and Rimantadine
Med Lett Drugs Ther. 2005 Nov 21;47(1222):93-5 | Show Full IntroductionHide Full Introduction